Trial Profile

A Phase Ib, open lable trial of orally administered DUR-928 for the treatment of non-alcoholic steatohepatitis (NASH) patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Larsucosterol (Primary)
Indications Non-alcoholic steatohepatitis
Focus Adverse reactions; Biomarker; Pharmacokinetics; Proof of concept
Sponsors DURECT Corporation

Most Recent Events

26 Jun 2021 Results for further analysis of efficacy signals from this trial, presented at The International Liver Congress 2021
23 Jun 2021 According to a DURECT Corporation media release, data from this study presented at the 2021 International Liver Conference (EASL).
23 Jun 2021 Results published in the DURECT Corporation media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com